Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tert-Butylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butylamine SCHEMBL28919679 | 1.00 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2ADORA1NR1H2SCN4A | |
| Tert-Butylamine SCHEMBL28919678 | 1.00 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2ADORA1NR1H2SCN4A | |
| SCHEMBL15606327 | 0.96 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2ADORA1NR1H2SCN4A | |
| SCHEMBL4547486 | 0.96 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2ADORA1NR1H2SCN4A | |
| SCHEMBL4869226 | 0.96 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2ADORA1NR1H2SCN4A | |
| SCHEMBL5837539 | 0.85 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2ADORA1NR1H2SCN4A | |
| SCHEMBL5837052 | 0.85 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2ADORA1NR1H2SCN4A | |
| SCHEMBL10215478 | 0.84 | NPC1 (0.41) | HSD17B10SMN1; SMN2NR1H2SCN4ANPC1 | |
| SCHEMBL8235326 | 0.84 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2NR1H2SCN4ANPC1 | |
| SCHEMBL17358752 | 0.84 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2NR1H2SCN4ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136620-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. | 2025-05-01 | — | — | US | disclosed |
| US-20240058457-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2024-02-22 | — | — | US | disclosed |
| EP-4263552-A1 | BTK DEGRADER | Guangzhou Lupeng Pharmaceutical Company Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023137225-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2022133184-A1 | BTK DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-2454252-B1 | Spiro amino compounds suitable for the treatment of (inter alia) sleep disorders and drug addiction | Rottapharm Biotech Srl (IT) | 2015-03-04 | — | — | EP | disclosed |
| US-8859608-B2 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-10-14 | — | — | US | disclosed |
| EP-2454252-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | Rottapharm S.p.A. (IT) | 2012-05-23 | — | — | EP | disclosed |
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM BIOTECH S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
| WO-2011006960-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM S.P.A. (IT) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | SLC1A1, SLC6A3, SLC1A2 | HSD17B10 1254/4885SMN1; SMN2 1894/4885ADORA1 490/4885 |
| US-20240058457-A1 | BTK DEGRADER | BTK, LYN, SYK | HSD17B10 2022/4885SMN1; SMN2 3282/4885ADORA1 3592/4885 |
| US-20250136620-A1 | BTK DEGRADER | BTK, CBL, LYN | HSD17B10 3451/4885SMN1; SMN2 3356/4885ADORA1 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.